Article Text

Download PDFPDF
Decline of the new Swedish variant of Chlamydia trachomatis after introduction of appropriate testing
  1. Kenneth Persson1,
  2. Berit Hammas1,
  3. Håkan Janson1,
  4. Carina Bjartling2,
  5. Joakim Dillner1,
  6. Lena Dillner1
  1. 1Department of Laboratory Medicine, Medical Microbiology, University Hospital Malmö, Malmö, Sweden
  2. 2Department of Obstetrics and Gynaecology, University Hospital Malmö, Malmö, Sweden
  1. Correspondence to Dr Kenneth Persson, Department of Laboratory Medicine, Medical Microbiology, University Hospital in Malmö, Malmö SE 205 02, Sweden; kenneth.persson{at}


Objective The longitudinal epidemiological development of the new variant of Chlamydia trachomatis was studied after appropriate testing procedures had been introduced when the strain was detected in 2006.

Methods The number of cases of the new variant of C trachomatis was followed from 2007 through 2011 from the laboratory records. Testing for C trachomatis is centralised to one laboratory with around 80–85 000 persons being tested annually in a population of 1.1 million.

Results During the 5-year period, 410 973 patients were tested of which 25 723 cases were positive. The proportion of the new variant of all positive cases declined from 30% in 2007 to 6% in 2011. While the number of the new variant of C trachomatis declined, the ordinary wild-type strains remained largely unchanged.

Conclusions A selective decline of the new variant of C trachomatis has occurred after appropriate laboratory testing was introduced. A new balance point between 5% and 10% for the new variant seems to be gradually approached.

  • Chlamydia trachomatis
  • epidemiology
  • bacterial infection
  • chlamydia infection
  • M genitalium
  • bacteriology
  • molecular biology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None.

  • Patient consent Anonymous laboratory data have been used.

  • Provenance and peer review Not commissioned; externally peer reviewed.